NSE · DRREDDY.NS
Dr. Reddy's Laboratories Limited
₹1,355.20+₹10.20 (+0.76%)
Dr. Reddy's Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 4.18% below the high.
Loading market information…
NSE · SPARC.NS · INR
Stock price, earnings
Quote as of Oct 30, 2026, 08:10 AM UTC. Cached market data; not a live quote.
One-year closing-price history · INR. Historical prices are not a forecast.
Sun Pharma Advanced Research Company Limited’s quoted price sits in the lower half of its reported 52-week range, 38.82% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Sun Pharma Advanced Research Company Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Sun Pharma Advanced Research Company Limited (SPARC), a biopharmaceutical firm established in Mumbai, India, in 2006 and operating as a subsidiary of Shanghvi Finance Private Limited, is globally committed to the discovery and advancement of innovative pharmaceutical products. The company's strategic focus involves developing novel chemical and biological entities, as well as improving existing formulations, with a key therapeutic emphasis on conditions within oncology, neurodegeneration, ophthalmology, and dermatology. SPARC currently commercializes Elepsia, a specialized levetiracetam formulation for managing epilepsy, and Xelpros, a latanoprost ophthalmic emulsion prescribed for the treatment of open-angle glaucoma or ocular hypertension. Its robust development pipeline showcases numerous candidates in various clinical trial stages: SDN-037, a difluprednate formulation in Phase 3 for addressing inflammation and pain linked to ocular surgery; PDP-716, also in Phase 3 for glaucoma; and phenobarbital sodium, targeting neonatal seizures. Additionally, the company is progressing Vodobatinib (SCO-088), which has concluded Part A of its Phase 1 study for resistant chronic myelogenous leukemia, and Vodobatinib (SCC-138), currently in Phase 2 for Parkinson's disease. Other pipeline assets include SCD-044, a Phase 2 candidate for psoriasis and atopic dermatitis, and SCO-120, advancing through Phase 1 for hormone receptor-positive, HER2-negative, metastatic breast cancer. Complementing its internal efforts, SPARC engages in strategic collaborations, including one with Bioprojet SCR to develop an S1P receptor 1 agonist for autoimmune disorders, and another with HitGen Ltd. aimed at identifying promising small molecule leads for selected therapeutic targets.
Latest available per-share figures in INR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:10 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₹1,355.20+₹10.20 (+0.76%)
Dr. Reddy's Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 4.18% below the high.
₹1,377.40+₹19.40 (+1.43%)
Cipla Limited’s quoted price sits in the lower half of its reported 52-week range, 13.61% below the high.
₹1,678.30+₹18.40 (+1.11%)
Aurobindo Pharma Limited’s quoted price sits in the upper half of its reported 52-week range, 3.56% below the high.
₹2,009.00+₹19.10 (+0.96%)
Lupin Limited’s quoted price sits in the lower half of its reported 52-week range, 20.6% below the high.
₹2,313.00-₹26.00 (-1.11%)
Glenmark Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 8.88% below the high.
₹1,928.60+₹2.40 (+0.12%)
Ipca Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 5.35% below the high.
₹1,866.60+₹1.60 (+0.09%)
Emcure Pharmaceuticals Ltd.’s quoted price sits in the upper half of its reported 52-week range, 11.14% below the high.
₹6,302.00+₹3.00 (+0.05%)
AstraZeneca Pharma India Limited’s quoted price sits in the lower half of its reported 52-week range, 36.02% below the high.
